SpeeDx has entered into an agreement with Cepheid for distribution of its PlexPCR and ResistancePlus molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy and the UK, will increase coverage for the ResistancePlus MG test, the first CE/IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.
The timing of the agreement coincides with recent guideline changes across Europe recommending M. genitalium resistance screening in the management of non-gonococcal urethritis. The inclusion of a macrolide resistance test when detecting M. genitalium provides clinicians with much-needed information to guide antibiotic treatment. Resistance to frontline antibiotic treatment is increasing and has been observed in up to 50% of M. genitalium-positive patients in recent studies.
“This partnership is a true win-win,” said Colin Denver (SpeeDx). “We gain better access to these important European markets and Cepheid can bring its customers a comprehensive test for M. genitalium and azithromycin resistance.”
Cepheid’s Dr David H Persing said: “SpeeDx offers an important approach to simultaneous detection of pathogens and drug resistance directly from clinical specimens, consistent with Cepheid's approach to detecting tuberculosis. This technology could be applied in multiple settings in which actionable treatment information is needed quickly."
SpeeDx specialises in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
